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This short review provides insight into the extent and effectiveness of patient involvement in the design
and evaluation of pictograms to support patient drug information. Pubmed, CINAHL, Cochrane Library,
Embase, PsycINFO, Academic Search Premier and Web of Science were searched systematically; the 73
included articles were evaluated with the MMAT. We see that, usually, non-patient end-users are
involved in the design of pharmaceutical pictograms – patients are more commonly involved in the final
evaluation of pictogram success. Repeated involvement of (non-)patients aids the design of effective
pharmaceutical pictograms, although there is limited evidence for such effects on patient perception of
drug information or health behaviour.Introduction
Patients often struggle to retain verbally communicated informa-
tion [1,2]. However, when written information about medication
is available for patients it is often not targeted to the needs of its
audience [3]. The use of informative stylised figurative drawings (i.
e., pictograms) [4] can help to improve the usability of drug leaflets
by drawing patient attention to important topics [5,6] and by
making information easier to understand and recall [4,7–9], which
can even lead to improved health behaviour [10]. Although there
are some common features for pictogram success, such as mini-
mising the amount of distracting detail and using the images in
combination with simple text [11], pictograms are not necessarily
universally understood – understanding can vary in particular
between different cultural groups and age groups [12–15]. There-
fore, it has been recommended to involve the target group in the
design and evaluation of pharmaceutical pictograms to gain in-
sight into their characteristics and to better tailor pictogram
interventions [16].
In the field of design, there has been increasing emphasis on
involving lay participants in an active rather than a passive role inCorresponding author: van Beusekom, M.M. (mvb4@st-andrews.ac.uk)
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1359-6446/ã 2018 The Authors. Published by Elsevier Ltddevelopment processes and on inviting end users during the ‘pre-
design phase’, to give them a voice in determining initial design
strategies [17,18]. Ranging from less to more active input, three
levels of user involvement can be distinguished [19–21]:
 An informative role (‘design for’): involving end users as passive
objects of observation for researchers.
 A consultative role (‘design with’): inviting end users to
comment on pre-defined pictogram designs.
 A participative role (‘design by’): involving end users in a way
that they can actively take part in the design and have decision
power regarding the design solution.
Despite extensive reviews on the use of pictures and pictograms
in health communication [11,22,23], little is known about user
involvement and its effectiveness in the design and evaluation of
pharmaceutical pictograms. However, it is has been suggested that
studies often do not involve relevant end users in effect measure-
ments of pictograms [24]. The aim of this review is therefore to
investigate the extent of lay – and in particular patient – end-user
involvement in the design and evaluation of pharmaceutical
pictograms and to find evidence on whether involvement in
the design process can increase the success of pictograms and
pictogram-enhanced drug information, so that future efforts of. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
https://doi.org/10.1016/j.drudis.2018.05.013
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evidence-based.
Study characteristics
All 73 articles that were found in a systematic search of databases
Pubmed, CINAHL, Cochrane Library, Embase, PsycINFO, Academ-
ic Search Premier and Web of Science (see supplementary material
A online) were published between 1993 and 2018, with over half
published since 2011. Most studies were conducted in the USA and
South Africa (17 and 13 studies, respectively), followed by Canada
and India (eight and five studies, respectively). Mixed-Methods
Appraisal Tool (MMAT) scores ranged from 25% to 100%. Almost
40% of the available studies intended to use their pictograms for
patients with low (health) literacy, a quarter of the studies aimed to
target ‘patients in general’ and about one-in-ten articles developed
pictograms for a specific age group.
Main pictogram series
The most frequently evaluated pharmaceutical pictograms are the
US Pharmacopeia Convention (USP) pictograms, reportedly devel-
oped by USP staff and redesigned in an iterative process with non-
native speakers of English, elderly and people with varying literacy
levels [16,25]. With the help of local participants, USP pictograms
were adapted for a South African audience, leading to the ‘SA’
pictogram series [24]. Dowse and colleagues also developed picto-
gram sets for HIV/AIDS medication with repeated and active
involvement of local participants [25,26]. By contrast, the Glyph
system, a project to create automated illustrations of patient
instructions [8], uses end users more as test subjects. A pictogram
series developed by the International Pharmaceutical Federation
(FIP) was designed for humanitarian medical missions with the
help of a variety of cultural communities [27]. A subarea of the
pharmaceutical pictograms field can be identified that is con-
cerned with images that communicate about effects of drugs
relating to driving [28–31].
User involvement and pictogram success
An overview of the main finding per outcome with respect to
whether or not an effect of end-user involvement on pictogram
success could be detected is presented in Table 1.
Pictogram ‘understandability’
Effects of user involvement in the design on pictogram
‘understandability’ (see Supplementary material Table B-1 online)
can be seen in particular when looking at the few studies that
evaluate more than one set of pictograms. A study that comparedTABLE 1
Effects of end-user involvement in design and final evaluation for
different outcomes
Outcome Effect of end-user
involvement in design?
Pictogram ‘understandability’ Yes
Opinion on pictograms Yes
Information understanding and recall Yes
Attention to information Unclear – possible
Opinion on label or leaflet Unclear – possible
(Pre-)intenders of health behaviour Unclear – likely
Health behaviour Unclear – contradictorypictograms developed by experts only to pictograms designed with
lay involvement found that the latter were understood better [28].
Other studies saw that the locally adapted SA pictograms scored
higher on ‘understandability’ than the original USP pictograms
[24,32]. A fourth study developed pictograms based on design rules
extracted from analysing USP pictograms and found better scores
for the existing USP pictograms than their new pictograms, which
had not been designed with end users [33].
These comparative studies imply that end-user involvement can
indeed have a positive impact on how well pictograms are under-
stood. Moreover, all studies that describe an extensive design phase
with several redesign iterations involving lay participants resulted in
highly understood pictograms [34–36], suggesting that repeated
involvement might be a particularly effective strategy to increase
the ‘understandability’ of pictograms. At the same time, the fre-
quently evaluated USP pictograms show great variation in
‘understandability’ scores between target groups that differ with
respect to country, age or literacy levels (see supplementary material
Table B-2 online). This is an indication that pictogram
‘understandability’ should always be understood in the context of
the intended target group. It should be noted that the only study in
whichallpictograms were sufficiently understood at initial exposure
didnot involve layend-users in the design at all. However, compared
to other studies, this article provided little information on the
development process and had a low MMAT score [37].
Opinion on pictograms
All studies that measured perceived usefulness of pictograms (see
Supplementary material Table B-3 online) and described a devel-
opment process involved non-patient end-users in the design and,
regardless of the exact moment or type of involvement, found that
the resulting pictograms scored well on perceived usefulness
[10,32,36,38–40]. In particular, low-literate end-users considered
pictograms to be useful [10,32,36,38]. Two studies that redesigned
pictograms based on consultative and informative input from lay
participants found that the pictogram translucency scores (i.e., the
perceived extent to which the pictogram manages to capture the
intended message) increased significantly for the redesigned pic-
tograms [41,42].
Involvement of lay participants in the design process led to
pictograms that were preferred by that specific target group but
were not necessarily universally preferred to other pictograms.
This became apparent from several studies that compared USP
pictograms to SA pictograms (see Supplementary material Table B-
3 online): when evaluated in South Africa, SA pictograms were
consistently preferred to USP pictograms [24,32,38]. An Indian
study, by contrast, found preference for USP over SA pictograms
[43]. Preferences for pictograms did not just differ between differ-
ent cultural groups but also varied between patients and medical
staff [44] and participants with adequate and low literacy levels
[45]. Two studies that involved non-patient end-users as early as in
the pre-design phase found that their pictograms were uniformly
valued within the target group [40,46].
Information understanding and recall
Active involvement of lay participants, often in a participatory role
and with patient end-users, was consistently seen to lead to a
positive effect of pictograms on participant understanding orwww.drugdiscoverytoday.com 1313
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Supplementary material Table B-4 online). Regardless of whether
participants were involved in an informative or consultative role,
all of these studies [8–10,47–52] made use of pictograms that had
been redesigned repeatedly with involvement of lay participants,
suggesting the importance of an iterative design process to opti-
mise pictograms for understanding or recall of information. By
contrast, studies that did not find an effect on understanding or
recall described no development process [53,54], used USP picto-
grams without adaptations [55] or described only one moment of
redesign with end users [7]. One study with an iterative design
process involving native and non-native speakers of a variety of
ages that evaluated their pictograms on a sample of elderly non-
native speakers found no effect on information understanding for
this group, but did find a positive effect for young native and non-
native speakers [51].
Attention to information
Studies that evaluated the effect of pictograms on the extent to
which participants pay attention to or notice information
[6,31,56,57] involved either potential (i.e., non-patient) or patient
end-users in the design phase, in informative or consultative roles,
and found that pictograms contributed positively to attention to
warnings [6], as well as the leaflet noticeability and likelihood of
reading [57]. Not enough data were available to compare effec-
tiveness of lay involvement in the design process. However, it was
seen that samples with different characteristics, such as different
cultures [31] or personal interests in the drug information [56],
varied in the impact they perceived the pictograms to have and in
how much attention they paid to the pictograms.
Opinion on label or leaflet
A similar effect was observed for outcomes relating to the per-
ceived effectiveness and user-friendliness of drug information, as
well as to preferences for different information formats. This was
illustrated by two studies that evaluated USP pictograms in the
USA: one study found no difference in perceived effectiveness
between leaflets with and without USP pictograms in a general
group of patients [58]; another study found that young partici-
pants perceived pictogram-enhanced information as more-effec-
tive than text-only information, but did not see this effect back in
the intended target group of elderly participants [57]. Also exam-
ining a subgroup within a sample of general patients provided
more-specific insights on patient perception of a drug label or
leaflets: a study found that a general group of patients preferred a
font-enlarged label to a pictogram label, but that elderly partici-
pants within this sample and those with a higher number of
morbidities preferred the pictogram label [49].
With respect to the effect of lay involvement in pictogram
development on how patients value resulting pictogram leaflets
or labels, it could be seen that, regardless of whether or not end
users had been involved in the design process or in what role,
pictogram information generally had a high acceptability with
respect to lay-out, liking of pictograms and amount of informa-
tion [39,59–64]. Studies that compared pictogram-enhanced in-
formation with verbal- or text-only information (see
Supplementary material Appendix B, Table B-6 online) almost
all involved lay participants in the pictogram design – only in the1314 www.drugdiscoverytoday.comexample described above did the overall group prefer the text-
only option [49].
(Pre-)intenders of health behaviour
All studies that described lay involvement in the design process
found positive effects for the pictograms on pre-intenders of
health behaviour such as self-efficacy, risk perception and behav-
iour change intention (see Supplementary material Table B-7
online). A study in which a pictogram-leaflet successfully in-
creased patient self-efficacy involved non-patient end-users re-
peatedly in an informative and consultative role in an iterative
design process [48]. Another study that compared pictograms
about driving with medication found that those developed in a
project with patient representatives conveyed a broader range of
risk severity levels and corresponded with a higher intention to
change behaviour compared with pictograms developed with
experts only [28]. Similar as for ‘attention to information’, it
was seen that the same pictograms could have different effects
on risk perception and intention to change health behaviour
between groups with different interests in the information pre-
sented [30].
Health behaviour
There was mixed evidence for the effect of end-user involvement
on health behaviour, including dosing errors and adherence (see
Supplementary material Table B-8 online); two studies that made
use of the SA pictograms found better adherence in the pictogram
leaflet group compared with the text-only group or those without a
leaflet [10,65]. At the same time, a study that involved local
patients from the very start of the pictogram development found
no difference in adherence between a pictogram, standard or font-
enlarged label [49]. A common factor for pictogram success in
terms of an effect on health behaviour appeared to be the involve-
ment of low-literate end-users in the evaluation [10,53,65–69].
Patient involvement
Many studies that develop or evaluate pharmaceutical pictograms
sample non-patient participants (Table 2). This has been described
as a less ‘challenging’ strategy when other characteristics of the
target group already considerably narrow the sampling pool, such
as when targeting low-literate patients [7]. In addition, access to a
bigger group of participants can improve the cost-effectiveness
and representativeness of a sample [70]. In this review, no differ-
ence could be detected of involving either patients or non-patients
in the design of pictograms. However, pictogram outcomes can be
improved by involving participants in the design with the same
main characteristics (e.g., cultural background and age range) as
the intended target group [24,32,51].
Groups with different cultural backgrounds, age range or litera-
cy levels were also seen to differ in how they understand or
evaluate pictograms. In addition, it was seen that samples with
different personal interests in drug information can differ in how
they perceive and respond to pictograms [31,49,56–58]. Together,
these findings suggest that, although involving non-patient end-
users in the development of pictograms is likely to lead to success-
ful pictograms also for patient end-users, it is advisable to perform
at least the final evaluation of pictogram success with actual
patients. This has also been addressed by several authors
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TABLE 2
Overview of moments, types and roles of end-user involvement
User involvement Studies that describe
a pre-design phase
(n = 8), % (n)
a design phase
(n = 39), % (n)
an evaluation
(n = 72), % (n)
Patients 0.0 (0) 7.7 (3)
[7,41,49]
22.2 (16)
[9,29,41,48–50,53,59,63–65,68,80–83]
Lay, non-patients 62.5 (5)
[5,8,46,51,71]
51.3 (20)
[8,25,26,28,34–36,40,42,44,
45,56,60,62–64,71,78,84,85]
73.6 (53)
[6–8,10,12,14,15,24–26,28,30–34,36–40,
42–47,51,52,54–58,60–62,66,67,69–71,77,78,84–91]
In informative role 12.5 (1)
[51]
15.4 (6)
[34–36,42,56,64]
84.7 (61)
[6–10,12,14,24–26,28–34,36–39,41–43,47–56,58–71,
77,78,80–84,86–90,92]
In consultative role 12.5 (1)
[71]
38.5 (15)
[8,25,35,36,41,42,44,45,49,
60,62–64,78,84]
50.0 (36)
[5,7,10,15,24–26,28,30,32,36–45,49–51,54,57–64,
78,81,82,85,87,91]
In participative role 50.0 (4)
[5,8,46,71]
10.3 (5)
[8,49,64,85]
1.4 (1)
[46]
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have to use a particular treatment might not have the same interest
to, for example, recall pictogram-enhanced written drug informa-
tion as patients would.
Type of involvement
Participants were most commonly involved in an informative and/
or consultative role in the design and evaluation of pictograms
(Table 2). Relatively few studies involve end users in a role with
creative freedom and decision power: the participative role [17].
However, early involvement of the target group in the develop-
ment of pictograms corresponds with a more active type of input:
lay participants in the pre-design phase are often involved in a
participatory manner, for example by sharing their information
needs [71], identifying topics that require visualisation [8] and
having decision power on the selection of pictograms [46].
When end users are involved in the ‘fuzzy front end’ of the
design (i.e., before initial design strategies are determined) [17]
designers have more opportunity to incorporate preferences of the
target group in the design in a more profound way compared with
when they can only make adaptations to pictograms at a later stage
of the development based on end-user feedback. Inviting end users
to participate in the pre-design phase can contribute to the devel-
opment of pictograms that are uniformly valued by the target
group [40,46]. Targeting end-user preference with respect to design
is essential, because pictograms that are viewed as appealing can
act as peripheral cues for patients to process and be persuaded by
information on therapy with low elaboration (i.e., with low levels
of active cognitive information processing) [72,73].
A successful strategy to optimise pictograms appears to be
repeated involvement of the target group, in an iterative design-
evaluation-redesign process. This strategy works well to develop
pictograms that are easily understood and valued by the target
group and possibly also helps to design pictograms that have a
positive effect on patient perception and understanding of written
drug information, as well as on their sense of self-efficacy. Every
design step that involves end users is an opportunity to gain more
insight into how pictograms can be improved to better match thetarget group’s information needs and preferences. An iterative
approach has been a widely adopted strategy also in other de-
sign-related fields, such as computer system design [74–76].
Incomplete descriptions and heterogeneity
A limitation of studies that describe the design or evaluation of
pharmaceutical pictograms, and consequently of this review, is
that many articles provide an incomplete description of samples,
materials and outcomes of evaluations, especially for intermediate
steps in the design process. For example, the size in which picto-
grams were presented to participants was described infrequently,
whereas pictogram size can affect how well they are understood
[77]. In addition, criteria to score participant interpretations of
pictograms as correct or incorrect are rarely provided, although
this could make a considerable difference in ‘understandability’
outcomes. In addition to the information gap that limits the
understanding of the context in which findings should be consid-
ered, there is considerable heterogeneity between studies. Sample
characteristics and evaluation methods vary and, although the
topic was limited to written drug information, the different mes-
sages that pictograms depict can affect their ‘understandability’
depending on how familiar participants are with them [78]. These
issues in comparability are of particular concern because very few
articles in the review directly compare different forms of end-user
involvement within one study, so that conclusions mainly relied
on similarities and differences between studies.
Implications and future research
Based on the available evidence, designers of new pictograms
are advised to clearly define the key characteristics of their
intended target group, to involve (non-)patient participants
with relevant characteristics early on and repeatedly in the
design process and to involve relevant patients or medication
users at least in the final evaluation of pictogram success. When
existing pictograms are used, care should be taken to select
pictograms that have been designed for and evaluated on a
population with similar characteristics to the patient group,
in particular with respect to age, literacy levels and culturalwww.drugdiscoverytoday.com 1315
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studies, limitations in our understanding of end-user involve-
ment in the context of pharmaceutical pictograms could be
addressed by research in the following areas. Developing or
identifying instruments that make it easier for end users to
contribute in a participative role. One of the few studies that
did attempt to involve end users in a participative role found
that their participants had no suggestions [8]. This is under-
standable, because thinking about solutions for drug informa-
tion or pictograms can be a little abstract or perhaps even
intimidating without proper guidance. More-interactive and
-engaging exercises should be explored in pictogram design
to scaffold idea-generation and make it more tangible and
stepwise for lay participants, such as ‘comicboarding’ – a meth-
od in which participants are encouraged to brainstorm about
solutions by filling in empty panels of a comic strip that intro-
duces the design problem [79].
In addition, although the focus of this review was to explore the
role of end users in design, it is also worth examining the role of
experts. Where lay participants are the experts of their own
experience, the design of pharmaceutical pictograms also draws
on expertise in design, pharmaceutical sciences and communica-
tion sciences. If a target group has specific visual needs, such as is
the case for a low-literate audience [45], it might also be advisable
to include an expert on the target group. In addition to exploring
effects of expert involvement, it would be interesting to see a truly1316 www.drugdiscoverytoday.comcollaborative pictogram design process, in which these different
experts sit around the table with lay participants and all players
have equal decision power [17].
Concluding remarks
This review shows that non-patient participants are often involved
in the development of pharmaceutical pictograms and provides
evidence that involving lay end-users in the design process helps
to increase the likelihood that resulting pictograms are well-un-
derstood, well-received and aid understanding and recall of drug
information they support. There is currently limited evidence for
an effect of user involvement on whether the developed picto-
grams help to improve patient perception of drug information or
their health behaviour. It is essential to involve participants that
meet the key criteria of the intended target group in the evaluation
of pictograms and pictogram-enhanced information, because it
was seen that different audiences can vary considerably in how
they perceive and respond to pictograms.
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